We read the recent innovative Letter by James and Sehgal, commenting on our article published in the European Journal of Internal Medicine and advocating for the development of a CRISPR-Cas9 gene therapy for Hereditary Hemorrhagic Telangiectasia (HHT) [1,2]. We appreciate all the authors’ comments and the opportunity to engage in a dialogue towards a curative therapy for HHT. The burden of recurrent epistaxis and vascular malformations’ complications on the patients' quality of life is indeed significant, and innovative therapies are urgently needed.
